Biomarkers in Oncology: Complexities in Biomarker-Driven Studies and Statistical Analysis
JCO Precis Oncol
.
2024 Jul:8:e2400358.
doi: 10.1200/PO.24.00358.
Authors
Hajime Uno
1
2
3
,
Miki Horiguchi
1
2
4
Affiliations
1
Division of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
2
Division of Biostatistics, Department of Data Science, Dana-Farber Cancer Institute, Boston, MA.
3
Department of Medicine, Harvard Medical School, Boston, MA.
4
Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA.
PMID:
39038245
PMCID:
PMC11268792
(available on
2025-07-01
)
DOI:
10.1200/PO.24.00358
Abstract
Biomarker-driven trials are key for precision oncology but challenge design and analysis.
Publication types
Editorial
Comment
MeSH terms
Biomarkers, Tumor* / analysis
Clinical Trials as Topic
Humans
Medical Oncology* / methods
Neoplasms
Precision Medicine
Substances
Biomarkers, Tumor
Grants and funding
R01 GM152499/GM/NIGMS NIH HHS/United States